Monday, February 26, 2024

Largest COVID Vaccine Study Yet Finds Links to Health Conditions; Study of 99 Million COVID-Vaccinated People Finds Links to Brain, Heart Problems, and other C-Virus related stories

Irfan Khan/Los Angeles Times/TNS 
Largest COVID vaccine study yet finds links to health conditions:
Vaccines that protect against severe illness, death and lingering long COVID symptoms from a coronavirus infection were linked to small increases in neurological, blood, and heart-related conditions in the largest global vaccine safety study to date.
The rare events — identified early in the pandemic — included a higher risk of heart-related inflammation from mRNA shots made by Pfizer Inc., BioNTech SE, and Moderna Inc., and an increased risk of a type of blood clot in the brain after immunization with viral-vector vaccines such as the one developed by the University of Oxford and made by AstraZeneca Plc.
The viral-vector jabs were also tied to an increased risk of Guillain-Barre syndrome, a neurological disorder in which the immune system mistakenly attacks the peripheral nervous system.
More than 13.5 billion doses of COVID vaccines have been administered globally over the past three years, saving over 1 million lives in Europe alone. Still, a small proportion of people immunized were injured by the shots, stoking debate about their benefits versus harms.
The new research, by the Global Vaccine Data Network, was published in the journal Vaccine last week, with the data made available via interactive dashboards to show methodology and specific findings.
The research looked for 13 medical conditions that the group considered “adverse events of special interest” among 99 million vaccinated individuals in eight countries, aiming to identify higher-than-expected cases after a COVID shot. The use of aggregated data increased the possibility of identifying rare safety signals that might have been missed when looking only at smaller populations.--->READ MORE HERE
Melissa Phillip/Houston Chronicle via AP, File
Study of 99 million COVID-vaccinated people finds links to brain, heart problems
In what stands as one of the most comprehensive vaccine safety studies across the globe, scientists have singled out unusual conditions that have surfaced after receiving COVID-19 vaccinations.
The study of 99 million vaccinated people in eight countries found a slight increase in heart inflammation cases following shots from Pfizer and Moderna, both mRNA vaccines.
Simultaneously, the AstraZeneca vaccine, which uses a different technology known as a viral vector, has been associated with a rare brain blood clot disorder.
The AstraZeneca vaccine has also been linked to a higher risk of Guillain-Barre syndrome, a neurological disorder that can sometimes lead to muscle weakness and, in rare instances, paralysis.
These findings are particularly significant against the backdrop of the 13.5 billion doses of COVID-19 vaccines administered globally to date — an undertaking that has played a critical role in preserving lives during the pandemic.
The Global Vaccine Data Network’s exhaustive research, detailed in the scholarly journal Vaccine, provides expansive insight into the matter. The network’s publication, equipped with easy-to-navigate dashboards, transparently presents both its research methodology and the conclusions drawn for public examination.
The analysts involved in this study examined health data of 99 million individuals, primarily focused on 13 specific conditions considered to be of special interest for vaccine safety. --->READ MORE HERE
Follow links below to relevant/related stories and resources:

‘Everything has a potential risk’: Largest COVID-19 study finds link between vaccine & heart, brain disorders

COVID vaccines linked to slight increases in heart, brain, blood disorders: study

USA TODAY: Coronavirus Updates

WSJ: Coronavirus Live Updates

YAHOO NEWS: Coronavirus Live Updates

NEW YORK POST: Coronavirus The Latest

If you like what you see, please "Like" and/or Follow us on FACEBOOK here, GETTR here, and TWITTER here.

No comments: